Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Pedro Ochoa-Allemant, Marina Serper, Roy X Wang, Helen Tang, Bachir Ghandour, Sarem Khan, Nadim Mahmud
BACKGROUND AND AIMS: The new steatotic liver disease (SLD) nomenclature introduced metabolic and alcohol-associated liver disease (MetALD), describing the intersection of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD). Waitlisting and liver transplantation for MetALD are not well-defined. We aimed to develop and validate an algorithm for identifying SLD phenotypes and assess trends in waitlisting and transplant outcomes. METHODS: We conducted a retrospective cohort study using the United Network for Organ Sharing registry, supplemented with detailed single-center data...
April 29, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#2
JOURNAL ARTICLE
Kiryu K Yap, Jan Schröder, Yi-Wen Gerrand, Aleksandar Dobric, Anne M Kong, Adrian M Fox, Brett Knowles, Simon W Banting, Andrew G Elefanty, Eduoard G Stanley, George C Yeoh, Glen P Lockwood, Victoria C Cogger, Wayne A Morrison, Jose M Polo, Geraldine M Mitchell
BACKGROUND & AIMS: Liver sinusoidal endothelial cells (LSECs) are important in liver development, regeneration, and pathophysiology, but the differentiation process underlying their tissue-specific phenotype is poorly understood and difficult to study because primary human cells are scarce. The aim of this study was to use human induced pluripotent stem cell (hiPSC)-derived LSEC-like cells to investigate the differentiation process of LSECs. METHODS: hiPSC-derived endothelial cells (iECs) were transplanted into the livers of Fah -/- / Rag2 -/- / Il2rg -/- mice and assessed over a 12-week period...
May 2024: JHEP reports: innovation in hepatology
#3
JOURNAL ARTICLE
Sven H Loosen, Fabian Benz, Raphael Mohr, Philipp A Reuken, Theresa H Wirtz, Lioba Junker, Christian Jansen, Carsten Meyer, Michael Praktiknjo, Alexander Wree, Johanna Reißing, Münevver Demir, Wenyi Gu, Mihael Vucur, Robert Schierwagen, Andreas Stallmach, Anselm Kunstein, Johannes Bode, Christian Trautwein, Frank Tacke, Tom Luedde, Tony Bruns, Jonel Trebicka, Christoph Roderburg
BACKGROUND & AIMS: Transjugular intrahepatic portosystemic shunt (TIPS) is the most effective therapy for complications of portal hypertension. However, clinical outcomes following TIPS placement vary widely between patients and identifying ideal candidates remains a challenge. Soluble urokinase plasminogen activator receptor (suPAR) is a circulating marker of immune activation that has previously been associated with liver inflammation, but its prognostic value in patients receiving TIPS is unknown...
May 2024: JHEP reports: innovation in hepatology
#4
JOURNAL ARTICLE
Sudha Kodali, Ashton A Connor, Elizabeth W Brombosz, R Mark Ghobrial
Cholangiocarcinoma (CCA) is a neoplasm of the biliary tract that has become increasingly prevalent throughout the world. Common risk factors for developing CCA include cirrhosis, primary sclerosing cholangitis, and trematode fluke infestation, although there are no set screening guidelines in high-risk groups. Lesions are typically identified via cross-sectional imaging and/or elevated serum carbohydrate antigen 19-9 levels, often followed by cytology or brushings with fluorescence in situ hybridization for confirmation...
March 2024: Gastroenterology & Hepatology
#5
JOURNAL ARTICLE
Nadia Ovchinsky, Madeleine Aumar, Alastair Baker, Ulrich Baumann, Philip Bufler, Mara Cananzi, Piotr Czubkowski, Özlem Durmaz, Ryan Fischer, Giuseppe Indolfi, Wikrom W Karnsakul, Florence Lacaille, Way S Lee, Giuseppe Maggiore, Philip Rosenthal, Mathias Ruiz, Etienne Sokal, Ekkehard Sturm, Wendy van der Woerd, Henkjan J Verkade, Andrew Wehrman, Christine Clemson, Qifeng Yu, Quanhong Ni, Jessica Ruvido, Susan Manganaro, Jan P Mattsson
BACKGROUND: In patients with Alagille syndrome, cholestasis-associated clinical features can include high serum bile acids and severe pruritus that can necessitate liver transplantation. We aimed to evaluate the efficacy and safety of the ileal bile acid transporter inhibitor odevixibat versus placebo in patients with Alagille syndrome. METHODS: The ASSERT study was a phase 3, double-blind, randomised, placebo-controlled trial that enrolled patients at 21 medical centres or hospitals in ten countries (Belgium, France, Germany, Italy, Malaysia, the Netherlands, Poland, Türkiye, the UK, and the USA)...
April 23, 2024: Lancet. Gastroenterology & Hepatology
#6
JOURNAL ARTICLE
Ilayda Ates, Callie Stuart, Tanner Rathbone, Mercedes Barzi, Gordon He, Angela M Major, Vijay Shankar, Rachel A Lyman, Sidney S Angner, Trudy F C Mackay, Shanthi Srinivasan, Alton Brad Farris, Karl-Dimiter Bissig, Renee N Cottle
BACKGROUND: We previously demonstrated the successful use of in vivo CRISPR gene editing to delete 4-hydroxyphenylpyruvate dioxygenase (HPD) to rescue mice deficient in fumarylacetoacetate hydrolase (FAH), a disorder known as hereditary tyrosinemia type 1 (HT1). The aim of this study was to develop an ex vivo gene-editing protocol and apply it as a cell therapy for HT1. METHODS: We isolated hepatocytes from wild-type (C57BL/6J) and Fah-/- mice and then used an optimized electroporation protocol to deliver Hpd-targeting CRISPR-Cas9 ribonucleoproteins into hepatocytes...
May 1, 2024: Hepatology Communications
#7
Akila Rajakumar, Prateek Gupta, Ashwin Rammohan, Vidya Devarajan, Dinesh Jothimani, Naresh Shanmugam, Ilankumaran Kaliamoorthy, Mohamed Rela
Although liver involvement has been observed in over two-third cases of dengue viral infection, less than 1% cases progress to dengue-related acute liver failure (D-ALF). Various aspects of management of this disease remain debated including the need and timing of liver transplantation (LT). Moreover, the outcomes of LT for D-ALF have been suboptimal. We present four contrasting cases of D-ALF, two managed with LT and the other two conservatively to highlight the management dilemmas concerning LT in D-ALF...
2024: Journal of Clinical and Experimental Hepatology
#8
JOURNAL ARTICLE
Abu Bakar H Bhatti, Syeda F Qasim, Zamrood Zamrood, Shahzad Riyaz, Nusrat Y Khan, Haseeb H Zia, Muslim Atiq
BACKGROUND AND OBJECTIVES: Acute-on-chronic liver failure (ACLF) is associated with high short-term mortality without liver transplantation (LT). The selection criteria for LT in these patients are not well defined. The objective of this study was to determine factors associated with post-transplant survival in ACLF. METHODS: This was a single-center retrospective study of patients who underwent living donor liver transplantation (LDLT) for ACLF between 2012 and 2022...
2024: Journal of Clinical and Experimental Hepatology
#9
JOURNAL ARTICLE
Manabu Hayashi, Kazumichi Abe, Tatsuro Sugaya, Yosuke Takahata, Masashi Fujita, Atsushi Takahashi, Hiromasa Ohira
AIM: Myostatin is a myokine involved in muscle mass regulation. The associations between circulating myostatin levels and clinical characteristics in patients with acute liver failure (ALF) and late-onset hepatic failure (LOHF) are unclear. METHODS: In this retrospective study, 51 patients with ALF or LOHF were included. Serum myostatin was measured using an enzyme-linked immunosorbent assay. RESULTS: Myostatin levels were significantly lower in patients with ALF and LOHF than in controls (ALF/LOHF: 2522 pg/mL, controls: 3853 pg/mL, p = 0...
April 24, 2024: Hepatology Research: the Official Journal of the Japan Society of Hepatology
#10
JOURNAL ARTICLE
Naga Chalasani, Eduardo Vilar-Gomez, Rohit Loomba, Katherine P Yates, Anna Mae Diehl, Brent A Neuschwander-Tetri, Srinivasan Dasarathy, Kris V Kowdley, Norah Terrault, Laura A Wilson, James Tonascia, Arun Sanyal
BACKGROUND AND AIMS: The patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 variant is associated with Steatotic Liver Disease (SLD) and its progression. We examined the association between PNPLA3 and the development of major adverse liver outcomes (MALO) and how non-modifiable and modifiable conditions modify this relationship. APPROACH AND RESULTS: 2,075 adults with biopsy-confirmed Metabolic-Associated SLD (MASLD) were enrolled in the MASLD CRN studies and followed prospectively until death, transplant, or withdrawal of consent...
April 23, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#11
JOURNAL ARTICLE
Alan L Hutchison, K Gautham Reddy, Sonali Paul, Anjana A Pillai
No abstract text is available yet for this article.
April 23, 2024: Liver Transplantation
#12
JOURNAL ARTICLE
Fredrik Åberg, Z Gordon Jiang, Helena Cortez-Pinto, Ville Männistö
Alcohol-associated liver disease (ALD), as highlighted in this narrative review, is a major public health concern, increasingly impacting global disease burden and premature mortality. In 2019, ALD accounted for the loss of 11 million life-years worldwide. The rising number of deaths and disability-adjusted life years attributed to ALD, particularly pronounced in America, are alarming. Projections suggest that the economic impact of ALD, as seen in the United States, could potentially double by 2040. ALD is increasingly prevalent among younger adults and has become the leading cause for liver transplantation in both America and Europe...
April 19, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#13
Jiajun Li, Sile Wan, Fukai Wen, Qingyu Li, Yifeng Cui, Zhaoyang Lu, Han Lin
Hepatic myelopathy (HM) is a rare neurological complication in the end stage of many liver diseases and is characterized by bilateral spastic paraparesis without sensory and sphincter dysfunction. It occurs owing to metabolic disorders and central nervous system dysfunction associated with cirrhosis. Without timely and effective clinical intervention, the prognosis of these patients is devastating. Although liver transplantation (LT) is an effective treatment for HM, the prognosis of these patients remains unsatisfactory...
April 28, 2024: Journal of Clinical and Translational Hepatology
#14
JOURNAL ARTICLE
Yongsheng Tang, Zenan Yuan, Xu Lu, Yingqiu Song, Shuguang Zhu, Chunhui Qiu, Qi Zhang, Binsheng Fu, Changchang Jia, Hua Li
BACKGROUND AND AIMS: Hepatic ischemia-reperfusion injury (HIRI) is a prevalent complication of liver transplantation, partial hepatectomy, and severe infection, necessitating the development of more effective clinical strategies. Receptor activity-modifying protein 1 (RAMP1), a member of the G protein-coupled receptor adapter family, has been implicated in numerous physiological and pathological processes. The study aimed to investigate the pathogenesis of RAMP1 in HIRI. METHODS: We established a 70% liver ischemia-reperfusion model in RAMP1 knockout (KO) and wild-type mice...
April 28, 2024: Journal of Clinical and Translational Hepatology
#15
JOURNAL ARTICLE
Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Hsing-Tao Kuo, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Cheng-Yuan Peng, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Jia-Horng Kao, Chun-Jen Liu, Chen-Hua Liu, Sheng-Lei Yan, Chun-Yen Lin, Wei-Wen Su, Cheng-Hsin Chu, Chih-Jen Chen, Shui-Yi Tung, Chi-Ming Tai, Chih-Wen Lin, Ching-Chu Lo, Pin-Nan Cheng, Yen-Cheng Chiu, Chia-Chi Wang, Jin-Shiung Cheng, Wei-Lun Tsai, Han-Chieh Lin, Yi-Hsiang Huang, Chi-Yi Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Wan-Long, Ming-Jong Bair, Ming-Lung Yu
BACKGROUNDS AND AIM: Chronic hepatitis C (CHC) patients who fail antiviral therapy have a high risk of developing hepatocellular carcinoma (HCC). We investigated the effects of metformin and statins, commonly used to treat diabetes mellitus (DM) and hyperlipidemia (HLP), on HCC risk in CHC patients who failed antiviral therapy. METHODS: CHC patients with failed interferon-based therapy were enrolled in a large-scale multicenter cohort study in Taiwan (T-COACH). HCC occurrence 1...
April 19, 2024: Clinical and Molecular Hepatology
#16
JOURNAL ARTICLE
L L Cao, J G Yan, D N Feng, Y Dong, Z Q Xu, F C Wang, Y J Gao, S S Zhu, M Zhang
Objective: To analyze the clinical manifestations, pathology, and gene variant characteristics in children with progressive familial intrahepatic cholestasis type 3 (PFIC3). Methods: This retrospective study assessed the clinical manifestations, pathological features, gene variants, and prognosis data of 11 children with PFIC3 hospitalized in the Department of Hepatology, Fifth Medical Center, PLA General Hospital, from January 2015 to December 2022. Panel or whole exome sequencing was performed on the probands, followed by Sanger sequencing for verification within the family...
April 16, 2024: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
#17
JOURNAL ARTICLE
Rheun-Chuan Lee, Po-Chin Liang, Huei-Lung Liang, Yung-Fang Chen, Chun-Yen Yu, Pin-Nan Cheng, Chien-Fu Hung, Cheng-Yuan Hsia, Hsueh-Chou Lai, Ming-Chih Ho, Yu-Fan Cheng, Yi-Sheng Liu, Yee Chao, Chien-Hung Chen
BACKGROUND AND AIM: The REgistry of Selective Internal radiation therapy in AsiaNs (RESIN) was a multicenter, single-arm, prospective, observational study of 90 Y resin microspheres in patients with hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC) from Taiwan. RESIN is the first real-life clinical study of this therapy in an Asian cohort. Study objectives were to evaluate the safety and efficacy of 90 Y resin microspheres. METHODS: Adults with HCC or mCRC scheduled to receive SIRT with 90 Y resin microspheres were included...
April 13, 2024: Journal of Gastroenterology and Hepatology
#18
JOURNAL ARTICLE
Winston Dunn, Yanming Li, Ashwani K Singal, Douglas A Simonetto, Luis A Díaz, Francisco Idalsoaga, Gustavo Ayares, Jorge Arnold, María Ayala-Valverde, Diego Perez, Jaime Gomez, Rodrigo Escarate, Eduardo Fuentes-López, Carolina Ramirez-Cadiz, Dalia Morales-Arraez, Wei Zhang, Steve Qian, Joseph C Ahn, Seth Buryska, Heer Mehta, Nicholas Dunn, Muhammad Waleed, Horia Stefanescu, Andreea Bumbu, Adelina Horhat, Bashar Attar, Rohit Agrawal, Joaquín Cabezas, Victor Echavaría, Berta Cuyàs, Maria Poca, German Soriano, Shiv K Sarin, Rakhi Maiwall, Prasun K Jalal, Fátima Higuera-de-la-Tijera, Anand V Kulkarni, P Nagaraja Rao, Patricia Guerra-Salazar, Lubomir Skladaný, Natália Kubánek, Veronica Prado, Ana Clemente-Sanchez, Diego Rincon, Tehseen Haider, Kristina R Chacko, Gustavo A Romero, Florencia D Pollarsky, Juan C Restrepo, Luis G Toro, Pamela Yaquich, Manuel Mendizabal, Maria L Garrido, Sebastián Marciano, Melisa Dirchwolf, Victor Vargas, César Jiménez, David Hudson, Guadalupe García-Tsao, Guillermo Ortiz, Juan G Abraldes, Patrick S Kamath, Marco Arrese, Vijay H Shah, Ramon Bataller, Juan P Arab
BACKGROUND AIMS: Alcohol-associated hepatitis (AH) poses significant short-term mortality. Existing prognostic models lack precision for 90-day mortality. Utilizing artificial intelligence (AI) in a global cohort, we sought to derive and validate an enhanced prognostic model. APPROACH AND RESULTS: The Global AlcHep initiative, a retrospective study across 23 centers in 12 countries, enrolled AH patients per NIAAA criteria. Centers were partitioned into derivation (11 centers, 860 patients) and validation cohorts (12 centers, 859 patients)...
April 12, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#19
REVIEW
Lukas Bethlehem, Maria Manuela Estevinho, Ari Grinspan, Fernando Magro, Jeremiah J Faith, Jean-Frederic Colombel
Microbiota therapeutics that transplant faecal material from healthy donors to people with mild-to-moderate ulcerative colitis have shown the potential to induce remission in about 30% of participants in small, phase 2 clinical trials. Despite this substantial achievement, the field needs to leverage the insights gained from these trials and progress towards phase 3 clinical trials and drug approval, while identifying the distinct clinical niche for this new therapeutic modality within inflammatory bowel disease (IBD) therapeutics...
May 2024: Lancet. Gastroenterology & Hepatology
#20
REVIEW
Serena Porcari, William Fusco, Igor Spivak, Marcello Fiorani, Antonio Gasbarrini, Eran Elinav, Giovanni Cammarota, Gianluca Ianiro
The gut microbiome is acknowledged as a key determinant of human health, and technological progress in the past two decades has enabled the deciphering of its composition and functions and its role in human disorders. Therefore, manipulation of the gut microbiome has emerged as a promising therapeutic option for communicable and non-communicable disorders. Full exploitation of current therapeutic microbiome modulators (including probiotics, prebiotics, and faecal microbiota transplantation) is hindered by several factors, including poor precision, regulatory and safety issues, and the impossibility of providing reproducible and targeted treatments...
May 2024: Lancet. Gastroenterology & Hepatology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
